Last update April 15, 2024

Ethyl 2-(4-chlorophenoxy)-2-methylpropionate

Incompatible

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Commentary.

Clofibrate, like other fibrates, decreases elevated blood lipids (triglycerides and cholesterol) by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and slightly decreasing cholesterol biosynthesis. (Miller 1998)

Since the last update we have not found published data in relation to breastfeeding.

Its high binding to plasma proteins makes it unlikely it will pass into breast milk.

If a fibrate is administered during lactation, it is advisable to choose those with a shorter half-life: Bezafibrate, Gemfibrozil.

It is advisable to follow a lipid-lowering diet and to practice regular physical activity daily, at least half an hour a day.

For considerations on the appropriateness of lipid-lowering treatment during lactation see Maternal hyperlipidemia, hypercholesterolemia, hypertriglyceridemia.

Due to increased mortality and other serious complications in patients treated with Clofibrate (Oliver 2012, WHO 1984), in most countries the product has been withdrawn from sale.


See below the information of this related product:

Alternatives

  • Bezafibrate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Colesevelam Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Colestipol Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Colestyramine (Safe substance and/or breastfeeding is the best option.)
  • Gemfibrozil (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Pravastatin Sodium (Safe substance and/or breastfeeding is the best option.)
  • Rosuvastatin Calcium (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Ethyl 2-(4-chlorophenoxy)-2-methylpropionate is Clofibrate in Chemical name.

Is written in other languages:

Ethyl 2-(4-chlorophenoxy)-2-methylpropionate is also known as

Group

Ethyl 2-(4-chlorophenoxy)-2-methylpropionate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ethyl 2-(4-chlorophenoxy)-2-methylpropionate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 243 daltons
Protein Binding 95 - 97 %
Tmax 6 hours
T½ 14 - 35 hours

References

  1. Oliver M. The clofibrate saga: a retrospective commentary. Br J Clin Pharmacol. 2012 Abstract
  2. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Abstract
  3. [No authors listed] WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1984 Abstract

Total visits

1,448

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM